Gelteq Limited Stock Price, News & Analysis

Gelteq (GELS) announced positive preclinical results on Jan 13, 2026 showing its oral gel delivery platform increased cannabidiol (CBD) absorption versus an FDA-approved oil product. Gelteq reported a greater than 22% increase in bioavailability and a higher peak exposure despite using a lower CBD concentration. The company says the platform enables precise, pre-measured dosing, faster uptake, and a non-invasive alternative to vaping.

Gelteq highlighted the Special Access Scheme (SAS) as a potential expedited pathway to earlier patient access in Australia and a stepping stone for global commercial partnerships and licensing opportunities.

Gelteq (NASDAQ:GELS) announced a partnership with the Hong Kong Flag Football Program on Dec 16, 2025 to integrate its gel-based hydration and sports performance formulations into men’s, women’s and youth national team training and competition.

The announcement cites recent regional commercial progress, including a China-focused sales agreement with Shenzhen Mana Health Management that carries minimum annual order commitments of at least USD $1.3 million. Gelteq noted prior adoption across Australia and Asia, including league-wide use on the Professional Pickleball Association’s PPA Tour Australia.

Gelteq (GELS) entered a three-year sales agreement with Shenzhen Mana Health Management to distribute Gelteq’s proprietary gel nutritional formulation across China.

The agreement includes minimum annual order volumes and Gelteq expects to derive a minimum of approximately USD $1.3 million in revenue during the three‑year term. Mana will use a multichannel network (digital plus offline retail) to promote a sugar‑lowering nutritional product and create a pathway to introduce additional Gelteq formulations in China.

Management said the deal builds on recent Asia sports product launches and aims to generate more predictable revenue and adoption of Gelteq’s gel delivery platform.

Gelteq (ASX:GELS) reported preclinical results showing its proprietary gel platform improved oral delivery of oil-soluble and poorly soluble drugs.

Key findings: a 300% increase in bioavailability within the first hour versus an existing FDA‑approved reference product and >20% higher overall absorption over 24 hours. Studies showed uniform small‑intestinal distribution, controlled GI transit, targeted release, effective absorption, and full clearance of API and gel material.

The company says the platform may reduce emulsifier needs, enhance bioavailability, and help reformulate challenging molecules across multiple therapeutic areas.

Gelteq (Nasdaq: GELS) announced that CEO Nathan Givoni will present at the Q4 Investor Summit Virtual on December 9, 2025 at 4:00 PM ET.

Mr. Givoni will discuss growth strategy, market positioning, and upcoming catalysts. He will also host one-on-one meetings with institutional and high-net-worth investors on December 10, 2025. Investors can request meeting access through the summit registration link or by contacting the conference or Gelteq investor relations at mkreps@darrowir.com. Event contact is fred@investorsummitgroup.com.

Gelteq (ASX:GELS) announced positive preclinical pharmacokinetic results on Nov 24, 2025 showing its proprietary gel formulation produced a 38–45% increase in systemic exposure (AUC) versus a leading marketed antihistamine, plus markedly higher Cmax and a comparable Tmax. The company said the test compound was water-soluble, supporting broader application of the gel platform across other water-soluble drug classes and strengthening plans to pursue an FDA approval pathway for an antihistamine and to engage pharmaceutical partners.

Gelteq (ASX:GELS) announced the commencement of a preclinical animal trial on October 23, 2025 to evaluate its proprietary gel-based oral formulation technology for oily and poorly soluble drugs. The study is being conducted with Monash University Institute of Pharmaceutical Science. The company highlights that >40% of marketed drugs and up to 90% of discovery candidates have low solubility, and notes the global industry spends more than USD $4 billion annually on delivery technologies. Gelteq said successful results could enable pipeline salvage, lifecycle extension, and reduced API dose size for clients.

Gelteq (ASX:GELS) entered a Product Development and Profit Share Agreement with Melbourne Health on October 9, 2025 to develop oral products containing HAMSB (high-amylose maize starch butyrylated), a compound linked in an Australian study to reduced bowel polyp initiation. The partners will use Gelteq's proprietary gel-based oral delivery platform and Gelteq's Clayton, Victoria facility will handle manufacturing, marketing, and commercialisation. The agreement includes a profit-sharing model granting Melbourne Health a share of net profits from future product sales. The program aims to create a ready-to-consume HAMSB product targeting preventive colorectal health and improved patient compliance.

Gelteq Limited (NASDAQ:GELS), a gel-based oral delivery solutions developer, announced the successful launch of its technology-enabled products in the U.S. market through its partnership with Healthy Extracts (OTCQB:HYEX).

This milestone marks Gelteq's transition from R&D to active commercialization in the U.S., with products now reaching their U.S. warehousing facility. The partnership, which began with warehousing and fulfillment arrangements, has progressed to active sales and distribution, demonstrating the potential of Gelteq's proprietary gel technology in the nutraceutical market.